Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II olaparib monotherapy in advanced castration-resistant prostate cancer
ISRCTN15124653Phase 2Completed
- Sponsor
- Institute of Cancer Research
- Start
- Jul 2012
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of olaparib in castration-resistant prostate cancer (CRPC), sponsored by Institute of Cancer Research. Primary endpoint: Composite response rate. Started Jul 2012; status: completed.
02
Drugs
olaparib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on ISRCTN15124653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15124653.